1.80
+0.135(+8.13%)
Currency In USD
| Previous Close | 1.66 |
| Open | 1.66 |
| Day High | 1.84 |
| Day Low | 1.66 |
| 52-Week High | 2.64 |
| 52-Week Low | 0.53 |
| Volume | 9.91M |
| Average Volume | 5.73M |
| Market Cap | 267.46M |
| PE | -0.87 |
| EPS | -2.07 |
| Moving Average 50 Days | 1.98 |
| Moving Average 200 Days | 1.19 |
| Change | 0.14 |
If you invested $1000 in Palisade Bio, Inc. (PALI) 10 years ago, it would be worth $0 as of January 20, 2026 at a share price of $1.795. Whereas If you bought $1000 worth of Palisade Bio, Inc. (PALI) shares 5 years ago, it would be worth $0.29 as of January 20, 2026 at a share price of $1.795.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
GlobeNewswire Inc.
Jan 16, 2026 1:30 PM GMT
PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis Carlsbad, CA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage
Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108
GlobeNewswire Inc.
Jan 07, 2026 1:15 PM GMT
PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) Carlsbad, CA, Jan. 0
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108
GlobeNewswire Inc.
Dec 30, 2025 1:35 PM GMT
PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) to address significant unmet medical needs Ongoing development of PA